Drug Approval | January 08, 2026
Briefs: Medicamen Biotech and Gland Pharma
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Subscribe To Our Newsletter & Stay Updated
